Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: August 2009
-
By Donald Zuhn — The U.S. Patent and Trademark Office has announced that on Thursday at 12:30 pm (EST), U.S. Secretary of Commerce Gary Locke will administer the oath of office to David Kappos (at right), the new Under Secretary of Commerce for Intellectual Property and Director of the USPTO. The new USPTO Director…
-
By Donald Zuhn — It has not been a great year for the biotech/pharma industry. In February, BIO President and CEO Jim Greenwood noted that almost a third of BIO's membership had less than six months of cash on hand, 45% had less than one year of cash remaining, and only 10% of the…
-
By Suresh Pillai — Jury Finds AGA Guilty of Infringement in Medtronic Dispute A jury in the U.S. District Court for the Northern District of California has ruled that AGA Medical Corp. infringed Medtronic Inc.'s patents for blood vessel occlusion devices, and has ordered AGA to pay Medtronic $57 million. This award is based…
-
By Mark Chael — Recently, Cytori Therapeutics, Inc. announced that the U.S. Patent and Trademark Office had issued a Notice of Allowance for claims directed to prosthetic devices seeded with adipose-derived stem cells. According to the press release, these claims are related to the use of Cytori's Celution® System for the treatment of bone…
-
By Donald Zuhn — Last month, Alnylam Pharmaceuticals announced that it would contribute more than 1,500 of its RNA interference (RNAi) patents to the patent pool established by GlaxoSmithKline earlier this year. Alnylam is known for the development of therapeutics based on RNAi for the treatment of respiratory syncytial virus (RSV) infection, liver cancer,…
-
By Mark Chael — For the benefit of our readers, we would like to remind you that the Office of PCT Legal Administration at the U.S. Patent and Trademark Office maintains a mailing list "to notify PCT customers, via e-mail, of updates to the forms and other information on [its] pages." In order to…
-
Common Sense, Perhaps, But Whose? By Kevin E. Noonan — The Supreme Court in KSR International Co. v. Teleflex Inc. established a standard (such as it is) of "common sense" in evaluating whether an invention is obvious. If the Court had been careful to follow the statute, it might have stressed more carefully that…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Sandoz Inc. v. Boehringer Ingelheim Pharma GmbH & Co. KG et al.1:09-cv-01444; filed July 31, 2009 in the District Court of the…
-
August 17-18, 2009 – Advanced Patent Prosecution Workshop 2009: Claim Drafting & Amendment Writing (Practising Law Institute) – San Francisco, CA September 1, 2009 – Prior Art & Obviousness 2009: The PTO & CAFC Perspective on Patent Law Sections 102 & 103 (Practising Law Institute) – San Francisco, CA September 13-15, 2009 – 2009 Annual…
-
American Conference Institute (ACI) will be holding its Patent Opinion Writing Boot Camp on October 28-29, 2009 in Philadelphia, PA. The conference will allow attendees to: • Identify how Seagate has altered opinion practice and the new standard for willful infringement;• Clarify business objectives to determine the ultimate purpose of the opinion and the anticipated…
Patent Docs 